54 FrielH.LedermanH
Abidi C, Rtibi K, Boutahiri S, et al
These metrics help guide treatment planning by identifying metabolic barriers that may affect inflammation control, tissue repair, and long-term response to peptide-based interventions
As of January 2025, efgartigimod is the only FcRn antagonist with registered (albeit in not all cases ongoing) trials within bullous pemphigoid, post-coronavirus disease 2019 (COVID-19) postural orthostatic tachycardia syndrome, membranous nephropathy, and antineutrophil cytoplasmic antibody-associated vasculitis, and disclosed development plans detail an investigation of efgartigimod within more than ten indications [245]
Storage and shelf life Proper storage determines how long your peptides remain effective
You know, maybe I know youre a clinical person that always just looks at heart attacks as a-an endpoint